

slaughtered within 28 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of enrofloxacin in this class of cattle may cause milk residues. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

(3) *Swine*. Use the product described in paragraph (a)(2) of this section as follows:

(i) *Amount*. Administer 7.5 mg/kg of body weight once, by subcutaneous injection behind the ear.

(ii) *Indications for use*. For the treatment and control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis*, and *Streptococcus suis*.

(iii) *Limitations*. Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose.

[72 FR 10597, Mar. 9, 2007, as amended by 73 FR 17890, Apr. 2, 2008; 73 FR 21819, Apr. 23, 2008; 76 FR 22611, Apr. 22, 2011]

§ 522.814 Eprinomectin.

(a) *Specifications*. Each milliliter of solution contains 50 milligrams (mg) eprinomectin.

(b) *Sponsor*. See No. 050604 in § 510.600(c) of this chapter.

(c) *Related tolerances*. See §§ 500.1410 and 556.227 of this chapter.

(d) *Conditions of use in cattle on pasture*—(1) *Amount*. Administer 1 mg/kilogram of body weight by subcutaneous injection.

(2) *Indications for use*. For the treatment and control of the following internal and external parasites: Gastrointestinal roundworms (adults and fourth-stage larvae) *Cooperia oncophora*, *C. punctata*, *C. surnabada*, *Trichostrongylus axei*, *Ostertagia ostertagi* (including inhibited stage); (adults) *Haemonchus placei*, *Oesophagostomum radiatum*, *O. lyrata*, *T. colubriformis*; lungworms (adults) *Dictyocaulus viviparus*; cattle grubs *Hypoderma bovis*; mites *Sarcoptes scabiei* var. *bovis*. Prevents reinfection with *C. oncophora*, *C. punctata*, and *T. axei* for 100 days following treatment; *H. placei*, *O. radiatum*, *O. lyrata*, and *O. ostertagi* for 120 days following treatment; and

D. viviparus for 150 days following treatment.

(3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Animals intended for human consumption must not be slaughtered within 48 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use in lactating dairy cows may cause drug residues in milk. A withdrawal period has not been established for pre-ruminating calves. Do not use in calves to be processed for veal.

[76 FR 72618, Nov. 25, 2011]

§ 522.820 Erythromycin.

(a) *Sponsor*. See No. 061623 in § 510.600(c) of this chapter.

(b) *Specifications*—(1) Each milliliter (mL) of solution contains 100 milligrams (mg) erythromycin base.

(2) Each mL of solution contains 200 mg erythromycin base.

(c) *Related tolerances*. See § 556.230 of this chapter.

(d) *Conditions of use*—(1) *Dog*. Administer product described in paragraph (b)(1) of this section as follows:

(i) *Amount*. 3 to 5 mg per pound (lb) body weight, intramuscularly, two to three times daily, for up to 5 days.

(ii) *Indications for use*. For the treatment of bacterial pneumonia, upper respiratory infections (tonsillitis, bronchitis, tracheitis, pharyngitis, pleurisy), endometritis and metritis, and bacterial wound infections caused by *Staphylococcus* spp., *Streptococcus* spp., and *Corynebacterium* spp., sensitive to erythromycin.

(iii) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) *Cats*. Administer product described in paragraph (b)(1) of this section as follows:

(i) *Amount*. 3 to 5 mg/lb body weight, intramuscularly, two to three times daily, for up to 5 days.

(ii) *Indications for use*. For the treatment of bacterial pneumonia, upper respiratory infections (rhinitis, bronchitis), secondary infections associated with panleukopenia, and bacterial wound infections caused by *Staphylococcus* spp. and *Streptococcus* spp., susceptible to erythromycin.

§ 522.840

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(3) *Cattle.* Administer products described in paragraph (b) of this section as follows:

(i) *Amount.* 4 mg/lb body weight by deep intramuscular injection once daily for up to 5 days.

(ii) *Indications for use.* For the treatment of bovine respiratory disease (shipping fever complex and bacterial pneumonia) associated with *Pasteurella multocida* susceptible to erythromycin.

(iii) *Limitations.* Do not use in female dairy cattle over 20 months of age. Do not slaughter treated animals within 6 days of last treatment. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. To avoid excess trim, do not slaughter within 21 days of last injection.

[72 FR 69142, Dec. 7, 2007]

§ 522.840 Estradiol.

(a) *Specifications.* Each silicone rubber implant contains 25.7 or 43.9 milligrams (mg) estradiol and is coated with not less than 0.5 mg oxytetracycline powder.

(b) *Sponsor.* See No. 021641 in § 510.600(c) of this chapter.

(c) *Related tolerances.* See § 556.240 of this chapter.

(d) *Conditions of use.* For implantation in steers and heifers as follows:

(1) *Amount.* Insert one 25.7-mg implant every 200 days; insert one 43.9-mg implant every 400 days.

(2) *Indications for use.* For increased rate of weight gain in suckling and pastured growing steers; for improved feed efficiency and increased rate of weight gain in confined steers and heifers. No additional effectiveness may be expected from reimplanting in less than 200 days for the 25.7-mg implant or 400 days for the 43.9-mg implant.

(3) *Limitations.* For subcutaneous ear implantation in steers and heifers only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating

21 CFR Ch. I (4–1–12 Edition)

calves. Do not use in calves to be processed for veal.

[69 FR 67818, Nov. 22, 2004]

§ 522.842 Estradiol benzoate and testosterone propionate.

(a) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use as in paragraph (c) of this section.

(1) No. 000856 for use as in paragraph (c)(1)(i), (c)(2), and (c)(3) of this section.

(2) No. 021641 for use as in paragraph (c) of this section.

(b) *Related tolerances.* See §§ 556.240 and 556.710 of this chapter.

(c) *Conditions of use.* For implantation in heifers as follows:

(1) *Amount.* (i) 20 milligrams (mg) estradiol benzoate and 200 mg testosterone propionate (one implant consisting of 8 pellets, each pellet containing 2.5 mg estradiol benzoate and 25 mg testosterone propionate) per implant dose.

(ii) 20 mg estradiol benzoate and 200 mg testosterone propionate (one implant consisting of 9 pellets, each of 8 pellets containing 2.5 mg estradiol benzoate and 25 mg testosterone propionate, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(2) *Indications for use.* For increased rate of weight gain and improved feed efficiency.

(3) *Limitations.* For heifers weighing 400 pounds or more; for subcutaneous ear implantation, one dose per animal; not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

[69 FR 68252, Nov. 24, 2004]

§ 522.850 Estradiol valerate and norgestomet in combination.

(a) *Specifications.* The product is a two-component drug consisting of the following:

(1) An implant containing 6.0 milligrams of norgestomet.

(2) An injectable solution (sesame oil) containing 3.0 milligrams of norgestomet and 5.0 milligrams of estradiol valerate per 2 milliliters.